Cleveland BioLabs (CBLI) Shares Volatile Following New Outperform Rating at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Cleveland BioLabs (NASDAQ: CBLI) with a Market Outperform rating and an $8 price target in a mid-day research note Wednesday.

The stock went parabolic following the intraday call. Shares surged as much as 7 percent, however quickly gave up gains. Cleveland Biolabs shares are now back down about 7.5 percent.

For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform
• RBC Capital Starts Krystal Biotech (KRYS) at Outperform